4/1
08:08 am
labp
Landos Biopharma, Inc. (NASDAQ: LABP) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.42 price target on the stock, down previously from $50.00.
Medium
Report
Landos Biopharma, Inc. (NASDAQ: LABP) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.42 price target on the stock, down previously from $50.00.